X
X
Total 393357 Results
| Label | Description | ILX | Version | Created CID | Modified Time | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dark blue | A color consisting of blue hue and low brightness. | ILX:0102793 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dark brown | ILX:0102794 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Dark cyan | A color consisting of cyan hue and low brightness. | ILX:0102795 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dark green | A color consisting of green hue and low brightness. | ILX:0102796 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dark grey | A color consisting of grey hue and low brightness. | ILX:0102797 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dark magenta | A color consisting of magenta with low brightness. | ILX:0102798 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dark Material | Irregularly shaped clumps of denatured or misfolded proteins observed in some neurons after a period of ischemia that stain heavily with osmium in electon microscopic preparations. | ILX:0102799 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dark orange | A color consisting of orange color and low brightness. | ILX:0102800 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dark pale pink | Pink color having medium brightness and low saturation. | ILX:0102801 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dark phase | The dark cycle phase. | ILX:0102802 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dark purple | A color consisting of purple color and low brightness. | ILX:0102803 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dark rearing paradigm | ILX:0102804 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Dark red | A color consisting of red hue and low brightness. | ILX:0102805 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dark red brown | ILX:0102806 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Dark violet | A color consisting of violet hue and low brightness. | ILX:0102807 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dark yellow | A color consisting of yellow hue and low brightness. | ILX:0102808 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Darunavir | Darunavir is a protease inhibitor used to treat HIV. It acts on the HIV aspartyl protease which the virus needs to cleave the HIV polyprotein into its functional fragments. Pharmacology: Darunavir is an inhibitor of the human immunodeficiency virus (HIV) protease. In studies, the drug, co-administered with ritonavir in combination therapy, significantly reduced viral load and increased CD4 cell counts in this treatment-experienced patient population (Tibotec, 2006, Product Monograph, Prezista 2006). Darunavir is used as an adjunct therapy with low dose ritonavir, which inhibits cytochrome P450 3A (CYP3A) which increases the bioavailability and half life of darunavir. Mechanism of action: Darunavir is a HIV protease inhibitor which prevents HIV replication by cleaving HIV encoded Gag-Pol polyproteins in infected cells, reducing viral maturation, load and increasing CD4 T lymphocytes. HIV destroys CD4 T lymphocytes which are an integral part of the immune system. Drug type: Approved. Small Molecule. Drug category: Antiviral Agents. HIV Protease Inhibitors | ILX:0102809 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dasatinib | Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinases inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR. Pharmacology: Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor Mechanism of action: Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFR. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression. Drug type: Approved. Investigational. Small Molecule. Drug category: Protein Kinase Inhibitors | ILX:0102810 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Data access protocol | ILX:0102811 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Data acquisition software | A resource that provides software that assists in measuring, recording, and collecting information about a physical phenomenon or physical property of an object (under investigation). Examples include the temperature or temperature change of a room, the reaction time of a response, digital picture acquisition. | ILX:0102812 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
About
Base community for the SciCrunch.org infrastructure
Contact Us
X